fda compounding semaglutide warning november 2025 The Risks of Compounded Products The FDA has received reports

We thank G

Semaglutide and tirzepatide have been under shortage pressure since 2023 as demand for the branded formulations (Ozempic, Wegovy, Mounjaro, Zepbound) outpaced manufacturing capacity

The brand matters less than the specification

Patients taking semaglutides 19 achieved total body weight loss of 5.9% at 3 months and 10.9% at 6 months, which may associated with other lifestyle interventions like diet

Participants who received retatrutide also started at 2 mg and titrated up to their target dose

However, some patients may experience symptomatic low blood pressure, particularly when combined with antihypertensive medications, during significant weight loss, or when dehydrated from gastrointestinal side effects